Endologix secures $20m in equity placement to expand sales network:
This article was originally published in Clinica
Endologix has raised $20m through the direct placement of 6.1 million shares with several unnamed institutional investors. The proceeds will enable the Irvine, California company to grow its sales force to 40-50 representatives by the end of the year and expand its marketing efforts in the US to commercialise its flagship product, the Powerlink system designed as a minimally-invasive treatment of abdominal aortic aneurysms. "Importantly, we believe we now have sufficient capital resources to operate our business to cash flow-positive operations," added Paul McCormick, Endologix' president and CEO.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.